clinical trial · NCT05179876
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Actelion·phase3·recruiting·n = 280
Hypertension, PulmonaryMacitentanSelexipagMacitentan/Tadalafil FDC
brief summary
The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies \[NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177, and NCT04175600\]), to continue to benefit from the intervention after closure of the parent study in case they have no alternative means of access to the study intervention. This study will allow assessment of the long-term safety of each study intervention.
started
May 4, 2022
primary completion
Jan 31, 2027
completion
Feb 29, 2028
last updated
Apr 13, 2026
official title
A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol